Your search for baricitinib returned 59 results
Drugs in the Pipeline
Investigational Oral Arthritis Tx Tops Adalimumab in Phase 3 Study
Eli Lilly and Incyte announced positive topline results of RA-BEAM, the fourth Phase 3 study of baricitinib for patients with moderately-to-severely active rheumatoid arthritis (RA).
Drugs in the Pipeline
Baricitinib Alone Authorized for COVID-19 Under Revised EUA
The update was based on data from the COV-BARRIER study.
EULAR 2017
Long-Term Baricitinib Effective, Safe for Moderate to Severe RA
Four Phase 3 clinical trials of baricitinib in the treatment of moderate-to-severe active rheumatoid arthritis enrolled patients who were methotrexate-naïve or had inadequate response to methotrexate, conventional disease-modifying antirheumatic drugs (DMARDs) or DMARDs with TNF inhibitors.
Trial Tracker
Baricitinib vs. Placebo or Adalimumab in Rheumatoid Arthritis
Taylor, Peter C. et al. "Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis"
News
Baricitinib Reduces Mortality in Critically Ill Adults With COVID-19
Reduction in death seen at 28, 60 days for patients receiving invasive mechanical ventilation, extracorporeal membrane oxygenation
Drugs in the Pipeline
Baricitinib Added to Topical Steroids Beneficial in Atopic Dermatitis Trial
Adding baricitinib to topical corticosteroids significantly improved disease severity in adult patients with moderate to severe atopic dermatitis, according to top-line results from BREEZE-AD7 study. The phase 3 study included 300 patients who had been diagnosed with moderate to severe atopic dermatitis for at least 12 months and had an inadequate response to topical medications.…
Drugs in the Pipeline
Baricitinib Receives Breakthrough Therapy Status for Alopecia Areata
The FDA has granted Breakthrough Therapy designation to baricitinib (LY3009104; Lilly), an oral Janus Kinase (JAK) inhibitor, for the treatment of alopecia areata.
Drugs in the Pipeline
Baricitinib Plus Remdesivir Cuts Time to Recovery for Hospitalized COVID-19 Patients
The ACTT-2 study began on May 8 and included more than 1000 patients.
